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1. INTRODUCTION  
 
1.1. Background 
 
The number and proportion of people older than 65 years is growing. It is estimated that 12% of the 
world population will be 65 years or older in 2030, and by the year 2050, that number will increase to 
17%1. In the US, the proportion of older adults is even higher, and by 2030, the geriatric population will 
comprise 20% of the American population2. While other special subpopulations, such as pediatrics, are 
seen as clear special clinical groups, less is invested in terms of research resources and clinical care 
training to support the care of older adults.  
The World Health Organization (WHO) has designated 2020–2030 as a “Decade of Healthy Ageing,”3 
and one of the approaches that WHO has identified to improve the care of older adults is to “develop 
and ensure access to services that provide older-person-centered and integrated care.” This approach is 
different than the one we usually consider in medical care and healthcare. As WHO states, “Health 
services are often designed to cure acute conditions or symptoms and tend to manage health issues in 
disconnected and fragmented ways that lack coordination across care providers, settings and time.”4 
While treating each condition separately might work in younger adults, the care that older adults 
require is different than that required by younger adults. Younger adult patients usually deal with 
individual health conditions, for which focused care and treatment might be appropriate. Older adults, 
however, have different medical histories and experiences, which also vary from patient to patient. As 
people age, they accumulate health conditions, and multimorbidity and chronic conditions become a 
major part of the health status of older adults. Treating one condition at a time in a patient who suffers 
from multiple conditions is not only inefficient, but also possibly physiologically impossible. In addition, 
the treatments themselves are not always appropriate for care in older patients, even if proven to be 
effective in younger patients. Furthermore, older adults are usually excluded from clinical trials, but 
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after drug approval, it is assumed that the effect of the drug on an older patient will be the same as that 
exhibited in younger patients. This assumption is unfounded, since our bodies and organs change as we 
age: the organs that are responsible for processing medications (the liver and kidneys) function 
differently in older age, and older patients are therefore exposed to higher risks of adverse effects of 
medications5. Finally, beyond the obvious differences in clinical and physiological conditions, older 
adults also often have different goals regarding care, and different life circumstances. For example, they 
might be interested in maintaining independence or a certain level of quality of life at the end of life, 
and not only in increasing survival time after diagnosis at any cost.  
The goal of developing older-person-centered and integrated care must be supported by evidence-
based guidelines and standards of care. An important aspect of any research study is obtaining the 
appropriate data on which to base the results and conclusions. The best evidence usually comes from 
randomized controlled trials (RCTs), the most common of which are clinical trials. However, older adults 
are unfortunately often underrepresented in such studies for various reasons, including health, 
economic burden on the patients and their families, communication issues, and ageism6,7. Nevertheless, 
even if they were regular participants in clinical studies, not every outcome or condition can be studied 
under such study design. This is especially true in studies in older adults when the exposures of interest 
might be chronic diseases (e.g. diabetes), long-term health behaviors (e.g. long-term smoking), or 
mental or cognitive state (e.g. loneliness or dementia). Moreover, the outcomes that are important in 
older adults might differ from those that are important in the treatment of younger adults (age 18–65). 
The latter group might be primarily interested in curing a disease or increasing survival time, even if that 
means enduring severe short-term side effects of therapy. In contrast, older adults might care more 
about subjective outcomes that are not currently measured in clinical trials. Their outcomes of interest 
might be more personal, such as managing symptoms and preserving independence and quality of life. 
In addition, aging is a long-term process, and the outcomes of interest in aging-related research (e.g. 
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mortality, cognitive and functional decline, chronic symptoms) are usually developed over a number of 
years, which is not a realistic follow-up time in RCTs. Therefore, these outcomes might be best 
measured using real-world data (RWDs), such as cohort studies, surveys, longitudinal studies, and 
administrative data.  
In this PhD project, we investigate how taking into consideration unique characteristics of older 
patients, as well as using appropriate research methods and data to study this group, would allow for 
better healthcare for this growing part of the population. As part of this PhD project, we performed two 
studies using RWDs, which examined the role of geriatric principles in care of older adults. In the first 
study, we used national survey of physicians to examine the use of potentially harmful first generation 
antihistamines in older adults. In the second study, we examined the patient relevant measures of well-
being in older adults diagnosed with multiple myeloma using longitudinal survey and claims data.   
The structure of this thesis is as follows. The reminder of Section 1 contains the background on the 
two topics that the PhD project focuses on – geriatrics principles in health care and RWDs. In subsection 
1.2. we starts with describing the geriatric principles of care, and presenting the rationale for using them 
in clinical care of older adults. Next, in subsection 1.3. we describe what RWDs are, and discuss their 
potentials and limitations in health care research. Section 2 presents the overall goal of this PhD project, 
as well as the detailed objectives of each of the two studies that are part of this PhD project. We 
summarize each study in detail in Section 3, including the methodology, main results, and the studies’ 
contribution to understanding the two topics of the PhD project (geriatric principles in health care and 
RWDs). The last subsection of Section 3, subsection 3.3., outlines the main conclusions the two PhD 
studies. Section 4 includes the bibliography of sources used in this PhD project. Finally, section 5 
includes the two publications included in this PhD project, as they were published.  
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1.2. Geriatrics Principles In Health Care 
 
It is becoming increasingly evident in clinical care that a more individualized approach may be 
more appropriate for the care of older adults. However, the current healthcare systems, most 
specifically in the US, are not set up to handle the complexities unique to older patients and the 
individual differences between patients. Clinicians, especially specialists, are often trained to treat the 
disease that a patient has been diagnosed with, and not the patient and his or her individual 
circumstances. It has been reported that 32% of the Medicare patients in the US undergo a surgical 
procedure in the last year of life8. While every case is different, and we can make no general statements 
about the need for or usefulness of those surgeries, it is clear that they were not lifesaving. The 
surgeries did, however, expose those patients to complications and possible hospital stays9. Healthcare 
decisions should always consider the benefits and risks of the procedures, and those considerations can 
be different in elderly patients, where the risks might be higher and the benefits lower.  
Linos et al. have proposed that clinical care decisions should be made with geriatric principles in 
mind2, where decisions are based not only on the characteristics of the diagnosed condition, but also on 
the characteristics (often aging-related) of the patient. The elements of such a geriatric framework 
include the following: life expectancy; lag time to benefit; multimorbidity, polypharmacy, and 
medication adverse effects; and function and cognition. These are explained below.  
Life expectancy. The risks and harms of intensive treatments and procedures may outweigh the benefits 
in patients who have short time to live. One example involves invasive surgeries for skin cancer that can 
lead to discomfort and complications. While the skin cancer is removed, it likely would not have become 
a major problem for a patient with a limited life expectancy. Surgery complications, however, do impact 
the daily life of the patient and might contribute to a decrease in quality of life and other negative 
outcomes. It has recently been demonstrated and adapted into clinical care that the life expectancy of 
older adults should play a role when deciding on certain types of cancer screening10,11 or cancer 
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treatment12. However, it is important not to conflict life expectancy with the chronological age of the 
patient. While older patients generally have high risks of death, patients’ life expectancy at any age can 
vary significantly depending on their health status. For example, an 80-year-old woman with one or two 
chronic conditions and no functional impairment has a median life expectancy of 12.6–14.3 years. On 
the other hand, a 65-year-old man with multiple chronic conditions and difficulty performing some 
instrumental activities of daily living (e.g. shopping and household chores) has a much shorter life 
expectancy of 5.0–7.2 years13. This indicates that both age and health status should be taken into 
account when making healthcare decisions.  
Lag time to benefit. While all interventions are developed to lead to improved health, not all of them 
lead to immediate or short-term benefits. This so called “lag time to benefit” has been estimated for 
many medications and screening procedures14, and it can vary from an immediate effect to a benefit 
seen only after several years. For example, Lee et al. showed that it takes approximately 11 years to 
prevent one death from breast cancer for every 1,000 mammography procedures performed today15. 
This means that in general mammography screenings make sense mostly for women whose life 
expectancy is longer than 10 years. It is important to balance the lag time to benefit of a specific 
treatment and the patient’s life expectancy when making treatment decisions, as some older patients 
might not live long enough to experience the benefits of the treatment, but might suffer from its 
immediate adverse effects and complications14.  
Multimorbidity, polypharmacy, and medication adverse effects. Under similar circumstances, and while 
being treated for similar conditions, older adults can experience complications that are not common in 
younger patients. One of the most obvious differences between the groups is that older patients are 
more likely to experience multimorbidity, since people accumulate health problems as they age. 
Multimorbidity by itself can be a problem, as the body is less likely to be able to handle additional 
diseases and treatments. Furthermore, multimorbidity can also lead to polypharmacy, which is 
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associated with several problems, such as interactions between different medications and overall 
increased risk of adverse events16–18. Another aspect increasing the risk of adverse events in older adults 
is that physiological differences between younger and older patients. Older patients bodies process the 
medications differently, and therefore the medications shown safe in younger adults might be risky in 
older adults19. 
Function and cognition. Functional and cognitive decline are common in older adults. Approximately 
20% of older adults report difficulty in performing one or more activities of daily living (bathing, 
dressing, eating, using the toilet, walking across the room, transferring from bed), and approximately 
21% of older adults have cognitive impairment20. Some functional and cognitive limitations might affect 
a patient’s ability to receive certain treatments (e.g. by not being able to visit the clinic or not being able 
to follow instructions). Patients with such functional and cognitive problems often need support from 
formal or informal caregivers. However, not all older adults have access to such support, and they might 
thus not be able to adhere to the planned treatment.  
The above-mentioned unique characteristics of older patients highlight the importance of 
physicians being aware of both the most updated guidelines for treatment of older adults and the 
priorities for older adults. As Linos et al. state12, “it is possible that some individuals would chose less‐
invasive treatment if they were given all relevant information. It is also possible that physicians would 
make different recommendations if they had more guidance (including decision tools or evidence‐based 
guidelines) on this topic.”  
 
1.3. Real-World Data  
 
Compiling appropriate data and finding evidence for the relationships between variables are the 
basis of any research. While the best evidence in medical research usually comes from RCTs, this design 
is not always possible in practice. In studies of older adults, it might not be possible for the investigator 
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to set the exposure of interest, which might be chronic diseases (e.g. diabetes), long-term health 
behaviors (e.g. long-term smoking), or mental or cognitive state (e.g. loneliness or dementia) - all which 
cannot be altered by the investigator. Moreover, the outcome might only be observed after a long 
follow-up time, which might not be practical in clinical trial studies. Alternative sources of evidence are 
observational data, based on RWDs, which includes data sources such as cohort studies, administrative 
data, and physician surveys. In this PhD project, we differentiate between RWDs that were collected for 
research purposes (e.g. cohort studies) and RWDs that were not originally intended for use in research 
(e.g. claims data or administrative data).  
We begin with a description of cohort studies. A cohort study involves a group of individuals 
who are observed, possibly interviewed or completed questionnaires, and followed for a period of time. 
As opposed to an RCT, where the investigator decides which participants receive the exposure, the 
participants’ exposure in cohort studies is pre-determined (by the participant, environment, or life 
history) and simply observed by the investigator. The outcome can be either observed as a part of the 
study or ascertained from links to other data sources (e.g. mortality ascertained from NDI or diagnosis 
ascertained from claims data or registries).  
There are several advantages to using cohort studies in aging-related research. One advantage is 
that multiple outcomes can be investigated – sometimes outcomes that were not even considered when 
the study was designed. In addition, the researchers have a high degree of control over what and how 
data are collected in survey studies, and they can include the exact questions that will address the 
specific particularities of their research question. Another advantage is that the follow-up time can be 
long, allowing for the study of long-term outcomes. Finally, in longitudinal studies, it is possible to 
observe variables before and after the exposure, if the exposure occurs during the study.  
Some of the strengths of large cohort studies are also their limitations. For example, the large 
number of participants and the long follow-up period both make cohort studies expensive. In addition, 
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as a consequence of the long follow up, the chance of loss to follow up is high, often because of the 
death of study members before outcomes other than death occur. Another limitation of long-term 
studies is that healthcare practices, such as diagnostic criteria and treatments, can change during those 
studies. These changes can affect a researcher’s ability to interpret the results.  
While cohort studies are designed for research purposes, large amounts of other potentially 
useful data are also inadvertently being collected every day in a real-world setting. Examples of such 
data are claims data, healthcare administrative data, and patients’ medical chart data, all of which are 
frequently collected based on convenience; therefore, data collection methods are not consistent with 
research methods. For example, many health insurance companies capture information on the medical 
encounters as well as treatments and medications of their customers for payment purposes. However, 
this data might be problematic for research, since we might only have information on what tests are 
performed, but not the results thereof. In the same way, we might only have information on procedures 
performed in a certain hospital, but not those performed on the same patient in other hospitals or 
outpatient settings. Similarly, we might only have a record of new medications prescribed at a specific 
doctor’s visit and not necessarily all the medications that a patient is taking at the time of the visit.  
Despite their limitations, these types of convenience RWDs can still be beneficial in research studies 
when used carefully and appropriately. While medical records or claims data can be messy because they 
are administrative data and not research data, and because they are collected usually for 
reimbursement purposes or for treatment records, such data also have several advantages. Data already 
exist in charts or computer systems, and access to them can be easier, faster, and cheaper than primary 
data collection. As a result, we might be able to generate cohorts of large sample sizes almost 
instantaneously. Furthermore, RWDs reflect real-world patterns of care, not those determined by study 
protocol. Finally, data mining approaches applied to RWDs can uncover key relationships that are not on 
clinical radar, thereby generating hypotheses to be studied in further, possibly experimental studies.  
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Regardless of study design and data type, research studies usually aim to compare two or more 
groups based on their exposure and to quantify the magnitude of the effect of the exposure on the 
outcome. Such comparisons are subject to confounding and the consequent biases generated. 
Confounding is present when subjects’ characteristics, both observed and unobserved, are not balanced 
between two comparison groups21. In RCTs, the balance of characteristics is usually achieved in the 
study design stage, when the groups are randomized before treatment assignment. In contrast, in 
observational studies, it is impossible to achieve this balance before the group assignment; therefore, it 
must be considered in the analysis stage.  
In the two studies included in this PhD project, we explored the use of matching methods to account 
for baseline differences in comparison groups. As one of the groups in each study had a small sample 
size, we had to carefully consider the following issues: matching methods, matching algorithms, and 
matching ratios21,22.  
In our studies, on the one hand, we explore the potential of the use of RWDs in aging-related 
research. On the other hand, we investigate and highlight the limitations of such data, and we 
emphasize the importance of using the appropriate statistical methods in the analysis and accounting 
for the limitations of the data in the interpretation of the results.  
2. OBJECTIVES  
The goal of this PhD project is twofold: 1) to examine the role of geriatric principles in care of older 
adults, 2) to explore the potentials and challenges of using RWDs in epidemiological and health 
outcomes studies of older adults. The first goal was explored by answering questions about the clinical 
care of older adults, both from objective (appropriateness of medication prescription and guideline 
adherence) and subjective (patient experience) perspectives. The second goal was explored by using  
multiple types of secondary data sources, including a physician survey (the National Ambulatory Medical 
Care Survey), a longitudinal cohort study (the Health and Requirement Study), and health insurance 
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claims data (US Medicare data). The results of our studies show how RWDs can be used to shed light on 
the experience of older adults when being treated for medical conditions. While we identify several 
limitations of the use of RWDs, we show how studies like this can provide valuable information which 
can be used to design further research studies on a specific topic.    
The specific aims of each of our studies were as follows:  
1. To examine medication prescription patterns in older adults – The first study addressed the 
following questions: Is it possible to assess prescription patterns of physicians based on a 
national physicians survey? From a clinical perspective, are patient characteristics taken into 
consideration when prescribing medications to older adults? Are some specialties of physicians 
more likely to follow the guidelines for appropriate medication prescription for older adults?  
2. To examine patient-relevant measures in older adults with multiple myeloma – The second 
study addressed the following questions: Is it possible to use large-scale longitudinal cohort 
studies, linked to Medicare data, to identify patients with a specific condition? Can we use 
cohort studies to describe patient-relevant outcomes and to examine the changes in patients’ 
experiences over time? How do the experiences of patients with a certain condition differ from 
those of healthy older adults?  
 
3. SUMMARY OF PUBLISHED STUDIES  
In this section we describe the two studies published as a part of this PhD project. For each study, 
we present the rationale for performing the study, the methodology used, and a short summary of the 
main results. Additionally, we describe how each study explored the two topics discussed in this PhD 
project – geriatrics principles in care of older adults, and use of RWDs.  
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3.1. Prescription of First-Generation Antihistamines in Older Adults  
 
The first study included in this thesis is titled, “A Multi-Year Cross-Sectional Study of US National 
Prescribing Patterns of First-Generation Sedating Antihistamines in Older Adults with Skin Disease.” It 
was accepted for publication in the British Journal of Dermatology on April 25th, 2019.  
Rationale: The clinical background for this study concerns the safe prescribing of first-generation 
antihistamines (FGAs) to older patients. Due to several known side effects in older adults ( e.g. cognitive 
impairment, falls ,confusion, and constipation23–27) the American Geriatrics Society (AGS) categorizes 
FGAs as potentially inappropriate for older patients19. In this study we examined the prescription rate of 
FGAs to older patients, and compared that rate among several subgroups (i.e., older vs. younger 
patients, different diagnoses, dermatologists vs. primary care physicians).  
Methods: We used data from the US National Ambulatory Medical Care Survey (NAMCS), 
between years 2006 and 2015, and we included in the study the visits of adult patients to dermatology 
offices and primary care physician (PCP) offices. The main outcome was prescription of any first 
generation antihistamine, which was reported by the treating physician at the time of the visit. Other 
main variables were: physician specialty, patient’s age and gender, diagnoses and other prescriptions at 
the time of the visit, and reason for visit. We compared the patients across different subgroups using χ2 
tests. We determined if any patient and physician characteristics  were independently associated with 
FGA prescription using multivariate logistic regression. Finally, we assessed the differences between 
dermatology and PCP visits using propensity score matching (PSM), to account for differences in patient 
characteristics between those two specialties.  
Main Results: Our study showed that dermatologists prescribed FGAs in 1.5% of visits by adults 
over 65 years, which is similar to the prescription rate of younger patients (1.2%, p-value=0.19). We 
observed some differences between older adults with and without FGA prescriptions:  those with FGA 
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prescriptions were more likely to have a diagnosis of dermatitis or pruritus, report an itch as the reason 
for their visit, have a chronic problem, and have six or more prescriptions at the visit. However, we did 
not find any association between FGA prescription and age, gender, or multimorbidity.  
The prescription rate of FGAs among older patients in PCP offices significantly higher than the 
rate in dermatology offices (4.5% vs. 1.5%, p-value < 0.001). Propensity score matching which included 
patient and visit characteristics revealed that even in the matched samples, the FGA prescriptions at 
dermatology visits were still lower than the rate at PCP visits (3.9% dermatology visits vs. 7.4% PCP 
visits, p-value = 0.02).  
Relevance to Geriatrics Principles: FGA prescription rates are similar regardless of age, gender, 
and multimorbidity, suggesting that many physicians do not follow geriatric principles, and are therefore 
potentially putting older and sicker patients at risk of adverse events, without evidence that those 
medications provide the desired therapeutic benefit to those patients.28 Our findings also show that 
dermatologists were less likely than primary care doctors to prescribe an FGA to patients with the same 
skin conditions or in similar clinical circumstances.  
Use of RWDs: Through the nationally representative cross-sectional survey of physicians, we had 
information on basic patient demographics, and diagnoses and medications for each office visit 
reported. While this kind of data gives a real-life picture of how physicians prescribe medications it also 
has several limitations: (1) the maximum number of reported prescriptions increased from eight in 2006 
to 30 by 2015, which might have changed the probability of recording FGAs over time. (2) physicians are 
not required to report a diagnosis code for the prescriptions, so we cannot assess the reason for 
prescribing FGA; (3) physicians are asked to record only the medications they prescribe at a specific visit, 
and this can lead to exclusion of FGA prescription prescribed on another visit that are still being taken by 
the patient;  (4) similarly, we cannot assess cumulative anticholinergic burden29 since we only have 
prescriptions from a specific visit.  
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Summary: The results of our study indicate that physicians overall do not follow the guidelines 
of the AGS for FGA prescriptions to older adults. Our study also demonstrates that different clinical 
specialists might be following different prescription patterns. Therefore, it might be possible to improve 
the care of older adults with dermatological conditions by encouraging a collaboration between 
dermatologists, geriatricians, and PCPs. Dermatologists might be more aware of proper treatments for 
skin conditions; geriatricians might be more aware of risks unique to older adults; and PCPs are most 
familiar with their patients’ overall health status and medical history. All three of those viewpoints are 
essential for the optimal care of older adults.  
Candidate contribution: The candidate (IC) was developed the concept of the study together with 
the senior author (Dr. Eleni Linos), and was responsible for designing and performing the analysis of the 
data and interpreting the results. The candidate also wrote the full manuscript.  
 
3.2. Patient-Reported Measures in Multiple Myeloma Patients  
 
The second study included in this thesis is titled, “Patient-Reported Measures of Well-Being in 
Older Multiple Myeloma Patients: Use of Secondary Data Source.” It was accepted for publication in 
Aging Clinical and Experimental Research on December 23rd, 2019. 
Rationale: Multiple myeloma (MM) is a rare disease that disproportionately affects older 
patients30. Due to its low prevalence in the population, recruitment of large number of multiple 
myeloma patients into research studies can be difficult. Here we aim to show that it is possible to create 
study cohorts of multiple myeloma patients using secondary data. The clinical side of the study focuses 
on the patient experience of the older multiple myeloma patients. We know that recent pharmaceutical 
developments lead to new treatments that increase the survival time in multiple myeloma patients31. 
However, it is not clear how the quality of life of older adults is affected by these treatments. 
18 
 
Understanding those effects is important, since older patients are more likely to suffer from treatment-
related adverse events than younger patients, but are at the same time more concerned with symptom 
management, the maintaining of independence, and quality of life32. In this study we examine the 
changes in patients’ well-being, and how these changes compare to changes attributed solely to aging of 
healthy older adults.  
Methods: In this study we identified older MM patients using the Health and Retirement Study 
(HRS) and Medicare claims. The measures evaluated in this study included activities of daily living (ADL) 
and instrumental activities of daily living (IADL) impairment, difficulty with walking and climbing stairs, 
vision and hearing impairment, significant pain, self-rated health, and depression. Those measures 
describe several aspects of well-being of older patients, and are included in the geriatric assessment33,34. 
We used McNemar’s test to compare the frequency of patient-reported measures (PRM) from before 
and after multiple myeloma diagnosis. Additionally, we used propensity score matching to compare 
change in PRMs between multiple myeloma patients and healthy older adults with similar baseline 
characteristics over the same time period.  
Main Results: We had access to Medicare claims of 26,044 HRS participants, and we were able 
to identify 92 patients with multiple myeloma in this sample. Our study showed an increase in 
impairments of PRMs after the multiple myeloma diagnosis, including increases in frequency of ADL 
difficulty, difficulty walking several blocks, and difficulty climbing one flight of stairs. Additionally, more 
patients reported experiencing hearing impairment, depression symptoms, and reporting poor or fair 
self-rated health after multiple myeloma diagnosis.  
Comparable HRS participants without MM diagnosis also reported increase in most impairments of 
PRM over the same period of time, but the increase was smaller than the one experienced by MM 
patients. For example, while 40% of the MM patients experienced increase in difficulty performing ADLs, 
27% of the HRS participants without MM diagnosis experienced it (p-value = 0.04).  Similarly, the 
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frequency of participants reporting depression symptoms is more than double among MM patients 
compared to HRS participants without the diagnosis (11% vs. 29%, p = 0.003).  
Relevance to Geriatrics Principles: Our study showed that measures that are important to older 
patients worsen after multiple myeloma.  However, the patient reported measures that we examined in 
our study are not usually considered priorities in  treatment of older persons with cancer, and they are 
rarely considered as outcomes in clinical trials of cancer treatments. We have also observed high 
mortality rate in our sample of older adults (20% one-year mortality). This high mortality rate and the 
reported decline in well-being suggest that supportive geriatric and palliative care should be a part of 
care of older patients with multiple myeloma.  
Use of RWDs: Our study demonstrated the following advantages of using longitudinal studies in 
research: (1) in studies with long study period, we can observe over time enough cases of even rare 
diseases; (2) because of the longitudinal nature of HRS, each participant is interviewed every two years. 
This means all measures are potentially observed before and after the diagnosis; (3) we have the same 
measures of well-being for a large sample of participants without multiple myeloma diagnosis. This 
means that we can use those healthy participants to  compare changes in the well-being  between 
healthy participants and patients with multiple myeloma diagnosis.  
Our study also demonstrates several limitations:  (1) multiple myeloma was identified from 
Medicare claims using ICD9 codes, but Medicare data does not include any test results that could 
confirm these diagnoses; (2)  We cannot explain if the changes in the well-being are due to the disease 
itself or specific treatments, since in our Medicare files we do not have information on treatments; (3) 
HRS interviews are conducted every two years, and are of course independently scheduled from 
multiple myeloma diagnosis. This means that the time between an interview and the diagnosis can 
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range from 0 days to two years, during which time the health status and the well-being of patients can 
change.  
Summary: We showed that it is possible to use secondary data to identify patients with rare 
diseases and create feasible study samples. While this and similar studies might be limited by some 
aspects of data collection, they still provide valuable exploratory and hypotheses-generating 
information. As showed by the results of this study, well-being of older patients worsens after MM 
diagnosis, and the decline and the mortality rate in this group are larger than the decline and mortality 
rate that healthy older adults experience as a normal part of aging. This indicates that multiple myeloma 
treatments of older patients should include not only the treatment of the disease itself, but also  
supportive geriatric and palliative care.   
Candidate contribution: The candidate (IC) developed the idea and the concept for the study, and 
she was responsible for performing the analysis of the data and interpreting the results. The candidate 
also wrote the full manuscript and prepared the poster for the presentation at the DAGStat conference 
in Munich in March 2019.  
 
3.3. Conclusions   
 
We performed two studies leveraging the use of RWDs in epidemiological and health outcomes 
research in the aging population. The two overall goals of the studies were to examine the use of the 
geriatric principles in clinical care of older adults and to assess the potentials of using RWDs in aging-
related research. Our studies have demonstrated that when analyzed appropriately and interpreted 
carefully, RWDs can be used to describe basic patterns of care and patient experience. While the use of 
RWDs unavoidably leads to some limitations in our studies, the results are nevertheless valuable in 
understanding the care and experience of older patients. The information obtained in these studies can 
21 
 
be used to generate hypotheses and design further studies. For example, our multiple myeloma study 
found that patient-reported measures are significantly affected after the diagnosis and those measures 
should thus be included in clinical trials.  
Regardless of the type of data used, our studies also highlight the importance of considering the 
geriatrics principles in clinical care of older adults. Physicians should balance the benefits and harms for 
an individual patient, as well as patient’s personal preferences. Physicians should consequently not 
follow one-size-fits-all guidelines. The guidelines for and the practice of clinical care for older adults 
should consider each patient’s unique characteristics, such as general health status, polypharmacy, 
cognition, and patient and family preferences.  
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